The induction of antibodies in vaginal secretions by systemic (intramuscular) immunization in humans was investigated by using the tetanus toxoid vaccine. Five women, 30 to 40 years old, were injected with a currently used dose of toxoid (40 IU), and serum, saliva, and vaginal secretion samples were collected on day 0 and on day 6 or day 10. All of these subjects had been previously vaccinated at least 5 years before; four were in good health, whereas one suffered from AIDS in clinical category B3. In most cases, analysis of specific antibodies in the vaginal wash showed a dramatic rise after boosting. These antibodies were primarily of the immunoglobulin G (IgG) (6, 9, 10, 19, 20) . Most of these antibodies consist of immunoglobulin A (IgA) polymers actively transported through epithelial cells after binding to the transmembrane secretory component (SC) (poly-Ig receptor). Secretory IgA (SIgA) is released into the lumen, where it remains bound to the SC (3). A role of SIgA antibodies seems to favor adherence of pathogens to mucus and thus their conveyance by the mucus stream. The presence of these antibodies in secretions is not correlated with the serum antibody level, and their induction by mucosal vaccination may be difficult. In vaginal secretions, the additional presence of significant levels of IgG has been reported (7, 8, 13, 28, (31) (32) (33) . This IgG might originate from local plasma cells (2, 4, 14, 15, 30) and/or transude from the circulation, as suggested by the low number of these cells in the mucosa (2, 4 l'Etoile, France), more than 5 years after their previous vaccine injection. One subject (no. 5) suffered from AIDS in the clinical category B3 according to the 1993 classification of the Centers for Disease Control. Serum samples, vaginal secretions, and saliva samples were collected before (day 0) and after (day 6 or day 10) injection. The vaginal fluids were collected by washing with 3 ml of phosphate-buffered saline (PBS) and centrifuged. The final supematant corresponded to approximately a 10-fold dilution of the original secretion. Except for subject 5, who suffered from amenorrhea, the vaccine injection was carried out during the follicular phase to avoid interference with menstruation. Hence, subject 1 was injected on day 6 of the menstrual cycle, subjects 2 and 4 were injected on day 8, and subject 3 was injected on day 11. No local infection was clinically apparent in any woman, and both washing and collection procedures were atraumatic. Resting mixed salivas were collected before meal time for 10 min and centrifuged. All samples were aliquoted and stored at -80°C until use.
The induction of antibodies in vaginal secretions by systemic (intramuscular) immunization in humans was investigated by using the tetanus toxoid vaccine. Five women, 30 to 40 years old, were injected with a currently used dose of toxoid (40 IU), and serum, saliva, and vaginal secretion samples were collected on day 0 and on day 6 or day 10. All of these subjects had been previously vaccinated at least 5 years before; four were in good health, whereas one suffered from AIDS in clinical category B3. In most cases, analysis of specific antibodies in the vaginal wash showed a dramatic rise after boosting. These antibodies were primarily of the immunoglobulin G (IgG) isotype. The specific activity (ratio of antibody titer to IgG concentration) was shown to increase after the booster injection, irrespective of variations in the IgG level during the menstrual cycle.
Comparison between serum and genital antibodies showed no difference in terms of both specific activity and level of avidity. These results demonstrate that parenteral injections can induce a systemic-derived antibody release in the vaginal fluid. Hence, systemic vaccinations can be efficient at the genital level and thus could reinforce or even replace a local vaccine.
Antibodies in secretions represent the first immune barrier against the entry of pathogens into the body throughout mucosae (6, 9, 10, 19, 20) . Most of these antibodies consist of immunoglobulin A (IgA) polymers actively transported through epithelial cells after binding to the transmembrane secretory component (SC) (poly-Ig receptor). Secretory IgA (SIgA) is released into the lumen, where it remains bound to the SC (3) . A role of SIgA antibodies seems to favor adherence of pathogens to mucus and thus their conveyance by the mucus stream. The presence of these antibodies in secretions is not correlated with the serum antibody level, and their induction by mucosal vaccination may be difficult. In vaginal secretions, the additional presence of significant levels of IgG has been reported (7, 8, 13, 28, (31) (32) (33) . This IgG might originate from local plasma cells (2, 4, 14, 15, 30) and/or transude from the circulation, as suggested by the low number of these cells in the mucosa (2, 4) . This release of serum antibodies in vaginal secretions might be of interest for vaccinations against AIDS and other sexually transmitted diseases.
In a previous study, our group has shown that antibodies to the human immunodeficiency virus (HIV) antigens in the vaginal fluid of infected patients are mainly of the IgG isotype (16 pool of normal sera served as a control curve. SIgA levels were measured by asymmetrical sandwich ELISA with coated antibodies to ot chain and peroxidase-labeled antibodies to SC (11) . Dilutions of SIgA, purified from human colostrum (12) , served as a control curve. Albumin levels were measured by a similar method, using coated rabbit antibodies and peroxidaselabeled rabbit antibodies to human serum albumin. Dilutions of purified human albumin (Sigma) served as a control curve.
Antitoxins ,ug/ml, and IgA ranged from 17 to 55 p.g/ml) of the cycle.
Nevertheless, the increase in total IgG could not explain the rise of IgG antitoxins, as shown by a simultaneous increase of the specific activity after the booster injection (Fig. 1) . More tion/serum IgG ratios, which remained close to 1 after the injection, whatever the degree of antitoxin response ( Table 1) . Investigation of the functional avidity of IgG antitoxins by thiocyanate dissociation in subject 1 ( Fig. 2A) , who was selected for her high level of responsiveness, and in the AIDS patient (Fig. 2B) showed identical curves for serum and for vaginal secretions.
To investigate whether the secreted IgG only diffused from the serum, albumin in the vaginal washes was measured and its level was compared with that of IgG. In the normal subjects, the albumin level was found to be relatively low, ranging from 8 to 18 ,ug/ml on day 0 and from 15 to 45 ,ug/ml on day 10. This level was higher in subject 5 (78 pug/ml on day 0 and 180 ,ug/ml on day 6), paralleling the IgG variation. Furthermore, a positive correlation was found between albumin and IgG levels (r = 0.83; P < 0.01) for all subjects.
Secretory antibodies. After absorption of IgG, which can interfere in the ELISA by competition with antitoxins of the other isotypes, no significant SIg antitoxin activity was detected in genital secretions of most patients, with only subjects 3 and 4 showing a very low response on day 10 (0.16 and 0.17 OD492, respectively). To ensure that this lack of activity was not due only to insufficient levels of SIgA in vaginal washes (ranging from 0.6 to 2.5 ,ug/ml on day 0 and from 5.9 to 16 ,ug/ml on day 10), antitoxins in saliva were also investigated (salivary SIgA ranged from 60 to 82 p,g/ml on day 0 and from 65 to 170 ,ug/ml on day 10). Similarly, the initial levels of salivary SIg antitoxins were very low (ranging from 0.07 to 0.3 OD492), and furthermore, no significant rise was observed after boosting (ranging from 0.1 to 0.32 OD492). As an internal control, antibodies to cell wall carbohydrates were clearly positive in all salivas (ranging from 0.56 to 1.05 OD492).
DISCUSSION
Investigating a possible induction of specific antibodies in vaginal secretions after parenteral injection of the antigen, we showed that the currently used tetanus toxoid vaccination leads to a substantial rise of local IgG antitoxins. These antibodies most likely have a systemic origin and can occur in the absence of specific SIg. The use of current methods of vaccination could thus be of major interest for prevention against sexually transmitted pathogens in humans, as a substitute for local immunization, when local immunization is not available, and/or as a complement to prolong the time of protection.
Human spontaneous genital antibodies of the IgG isotype are most often against the pathogens and alloantigens which reach the immune system via the genital route. Hence, it has 3960 BOUVET ET AL. not been established whether the local-regional and the systemic immune systems are involved alone or simultaneously in these cases. Experimental investigations with rodents showed antibodies of the IgG isotype both in serum and in vaginal secretions after intravaginal immunization with purified antigens (21, 25) as well as with live microorganisms (5, 18) . It has been shown that mice (25, 26, 29) and sheep (24) immunized by the subcutaneous route develop a high antibody response of the IgG isotype in the vagina. Similar results were obtained in monkeys immunized with native (22) or formalin-treated (17) simian immunodeficiency virus. For humans, it was also observed that systemic vaccination against killed polio vaccine can induce both serum and vaginal antibodies of the IgG isotype (23) . Nevertheless, all these experimental studies focused mainly on IgA antibodies, and therefore the IgG responses were not extensively investigated.
We (34) . Similarly, in humans both IgG-positive cells, which might be nonimmunocytic cells having taken up IgG from the interstitial fluid (2) , and IgGpositive glands were found to increase in the endometrium during the luteal phase (2) .
In the vaginal washes of normal subjects, the IgG/total IgA ratio was close to that in serum (i.e., -8) and differed significantly from the values (0.5 to 4) reported in previous studies (7, 8, 13, 28, 32, 33) , but it was in agreement with the results of a more recent study (31) . These differences seem to be related to a higher estimation of IgG in our study, probably because the samples were centrifuged immediately after collection instead of being stored frozen without preliminary cell removal. Indeed, this method prevents the release of cellular proteases during thawing and thus prevents degradation of IgG and, to a lesser degree, of nonsecretory IgA. In contrast, SIgA is known to be resistant to most proteases. The IgG concentration found in our study was ca. 31-fold (median value) higher than that of SIgA in the vaginal secretions. Even if SIgA could have been underestimated by competitive inhibition with monomeric IgA during the ELISA, this ratio clearly differs from the ratio of IgA to IgG plasma cells in both cervical and endometrial mucosae (2, 14) , but it is in full agreement with the large amount of extracellular IgG recently found in these tissues (4) . From this latter study (4), it seems that both mucosal and serum-derived IgA polymers are actively translocated through the endometrium epithelial cells to form endoluminal SIgA. Provided that serum-derived albumin was not degraded and/or selectively reabsorbed, its low level in the vaginal secretions, compared with that of IgG, suggests that passive transudation alone cannot explain the high level of IgG. Local synthesis and/or transport mechanisms, e.g., via Fc-y receptors, must also be envisaged. The Ig transudation might be through the endometrium and cervix (4) , since the squamous epithelium of the vagina seems unfavorable for diffusion (15) . 
